Nimotop (Nimodipine)

Nimodipine blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This inhibition reduces calcium entry, leading to selective dilation of intracranial vessels, enhanced cerebral blood flow, and a lower likelihood of vasospasm after a subarachnoid hemorrhage.

The dosage of Nimotop is determined by the prescribing clinician based on the patient’s clinical condition, weight, and renal or hepatic function. Healthcare professionals follow local guidelines and product labeling to set the appropriate infusion rate and duration.

Safety data for nimodipine in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Nimodipine is distinguished by its high lipophilicity and preferential action on cerebral vessels, whereas many other calcium channel blockers primarily affect systemic vasculature. This selectivity makes nimodipine especially useful for preventing vasospasm after subarachnoid hemorrhage, a benefit not shared by all agents in the class.

Nimotop should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Once removed from controlled storage, use the product within the time frame specified in the label.

Nimotop is supplied as an intravenous solution and is administered by slow infusion through a dedicated IV line. The infusion rate and total daily dose are set by the treating physician, who monitors blood pressure and neurological status throughout the treatment period.

The most serious adverse events include severe hypotension, myocardial infarction, hepatic dysfunction, and rare allergic reactions such as anaphylaxis. Prompt recognition and management of these conditions are essential, and patients should be closely monitored during therapy.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. Caution is also advised for individuals with uncontrolled severe hypotension, significant cardiac conduction abnormalities, or those receiving interacting medications that could precipitate dangerous blood‑pressure changes.